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Summary In the years 1979-1982, 83 patients with malignant teratoma of the testis who had retroperitoneal
adenopathy at presentation or after a period of surveillance were treated. Complete radiological resolution of
disease was obtained in 34 patients and a residual mass remained in 26, the remainder having progression of
the para-aortic or other metastatic disease. There was no para-aortic relapse in 47 patients receiving
radiotherapy post-chemotherapy whereas 2/11 who did not receive radiotherapy or an immediate
retroperitoneal node dissection relapsed. Morbidity from radiotherapy was minimal apart from subcutaneous
fibrosis in the irradiated area of 6 patients. It is concluded that radiotherapy is effective in sterilising minimal
residual tumour post-chemotherapy and may be considered as an alternative to surgery.
Chemotherapy is now established as an effective
treatment for metastatic teratoma of the testis
(Muggia, 1985; Peckham, 1985). However following
treatment a residual mass is common usually in the
para-aortic nodes but also in the mediastinum or
lungs. This may represent necrotic material or
differentiated teratomatous elements. The concern
is that there may be active tumour present or that
differentiated elements may ultimately reactivate
(Blandy, 1985). Surgical excision of the residual
mass is common practice and in most specialised
centres retroperitoneal node dissection (RPND) is
routinely performed post-chemotherapy. It has been
reported that prognosis is related to the
completeness of the excision (Tait et al., 1984).
Such surgery can be associated with considerable
morbidity and occasional mortality (Donohoe &
Rowland, 1981; Skinner et al., 1982). Localised
teratoma is however moderately radiosensitive
(Peckham & Barrett 1981a) - comparable with
squamous carcinoma of the head and neck or
transitional cell carcinoma of the urinary bladder -
and an alternative approach is to irradiate residual
masses post-chemotherapy. This paper describes the
use of radiotherapy post-chemotherapy in place of
routine surgical excision in those patients with
retroperitoneal lymphadenopathy at presentation.
Emphasis has been placed on examining the
incidence of local failure in the para-aortic area
rather than the results of chemotherapy which have
been described elsewhere (Wilkinson, 1985).
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Patients and methods
Between 1979 and 1982, 164 previously untreated
patients with malignant teratoma of the testis or
retroperitoneum were referred to this Institute
for management. All patients had histological con-
firmation of malignancy either by orchidectomy,
laparotomy or supraclavicular node biopsy and the
material was reviewed in all instances. All patients
had clinical examination, chest radiology, serum
alpha-foetoprotein (AFP) and beta chorionic
gonadotrophin (HCG) estimation and routine
biochemical and haematological profiles. Computed
tomography of the abdomen was performed in 145
patients, the remaining 19 being considered too ill
at presentation for the examination. Seventy-seven
patients had no evidence of retroperitoneal
adenopathy at any time and are not considered
further in this study. Computed tomography of the
chest was performed if the chest radiograph was
normal.
Stage one patients were entered into a sur-
veillance study (Read et al., 1983) and all other
stages received chemotherapy except for patients
treated at the beginning of 1979 Who received radio-
therapy as the primary treatment. Chemotherapy
was given for two courses beyond marker remission
or if there was no elevation of marker levels four
courses were given for patients with small volume
disease and six courses for bulky disease (Wilkinson,
1985). Patients with retroperitoneal lymphadeno-
pathy received radiotherapy one month after
completion of chemotherapy when bone marrow
function had recovered. Fields were directed to
the para-aortic nodal area (and when involved the
iliac nodes) using a parallel pair of opposed fields
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from a 4 or 8 MV linear accelerator. A central
midplane dose of between 3,500 and 4,000cGy
was given in 16 or 20 fractions over 22 to 28 days
(Gibb & Read, 1985). The treatment was sub-
sequently modifiedwith part ofthe tumourdose being
given by a rotation technique. Masses remaining
after radiotherapy were kept under observation by
further computed tomography of the abdomen. The
maximal cross-sectional area of the retroperitoneal
adenopathy was obtained from two measurements
at right angles on scans obtained before and after
chemotherapy, after radiotherapy and on scans
obtained from subsequent follow-up.
Results
Eighty-three patients had evidence of retroperi-
toneal adenopathy either at presentation or after a
period of surveillance. Of these patients 47 had
retroperitoneal lymphadenopathy which was less
than 5 cm maximum transverse diameter on CT of
the abdomen, 19 adenopathy more than 5cm
diameter and 17 had a palpable abdominal mass.
Four patients were not assessed by CT at
presentation but were clinically negative. Eighty-one
patients received chemotherapy as follows: PVB 21,
BeVIP 34, PEV 5day 10, PEV 24hour 14 and other
combinations 2. Five patients received radiotherapy
as a primary treatment and one mentally
subnormal patient with advanced disease did not
receive any treatment. The chemotherapy schedules
used are shown in Table I. The outcome of
treatment in the 87 patients is summarised in Table
II. In 34 patients there was complete radiological
resolution (CR) of the para-aortic disease and in 26
patients there was radiological evidence of a
residual mass (RM) despite the return of tumour
Table I Chemotherapy schedules
PVB
cis-platinum 20 mg m -2
vinblastine 6mg m-2
bleomycin 15mg b.d.
BeVIP
cis-platinum 20mgm -2
etoposide IOOmgm-2
vinblastine 6 mg m-2
bleomycin 30 mgi.m.
PEV
cis-platinum 20 mg m-2
etoposide 100mgm-2
vinblastine 10mg
PEV 24h
cis-platinum 100mgm-2
etoposide 150mg m-2
vinblastine 10mg
days 1-5
days 1 and 2
days 1-3
days 1-5
days 1-3
days and 2
every 21 days
days 1-5
days 1-3
days 1 and 2
24h infusion
days 1 and 2
day
All cycles given every 3 weeks.
marker levels to normal. These patients were then
considered for radiotherapy. In 21 patients there
was progression of the para-aortic or other
metastatic disease judged by persistent elevation of
marker levels or radiological progression. In general
these were patients with advanced large volume
disease and all have subsequently progressed and
died. There were two intercurrent and one
treatment related deaths. Two patients did not have
a reassessment of the para-aortic area after
completion of treatment, one patient with para-
aortic disease less than 5cm at
presentation is alive and disease-free, the other pre-
sented with advanced generalised disease including
a palpable para-aortic mass. He was treated with
chemotherapy followed by radiotherapy to
a residual mediastinal mass but there was no re-
Table II Outcome of treatment in relation to size of initial para-aortic mass
Outcome
Dead
Initial CR not Inter- Not
mass No. CR RM obtained current TReatment rescanned
<5cm 47 31 9 5 1 0 1
>5cm 19 3 11 5 0 0 0
Impalp 4 (la) 1 2 0 0 0
Palp 17 0 5 9 1 1 1
Totals 87 34 26 21 2 1 2
aNormal scan after treatment.
CR =complete radiological resolution; RM =radiological evidence of residual mass.RADIOTHERAPY AFTER CT IN NSGCT 625
assessment of the para-aortic area. He subsequently
had a generalised relapse including the para-aortic
area.
Complete response patients
The stages of the patients at treatment were IIA 17,
IIB 1, III 1, IVA 6, IVB 7 and IVC 1. The sizes of
the initial masses are shown in Table II. The
pathological classifications are shown in TableIII.
The chemotherapy received by the CR patients was
PVB 8, BEVIP 14, PEV 5 day 1, PEV 24 hour 7.
Four patients received radiotherapy only as an
initial treatment. Seven patients did not receive
radiotherapy after chemotherapy and these all had
minimal disease before treatment.
Twenty-eight of the 34 patients are alive with no
recurrence. Three patients who had received radio-
therapy to the para-aortic area only as an initial
treatment relapsed in the lungs, two received
successful chemotherapy and one died from treat-
ment related septicaemia. One patient died from
liver metastases five months after completing treat-
ment, one patient died from cerebral relapse after
three months and one patient who had received
successful chemotherapy developed a tumour of the
contralateral testis 38 months later and sub-
sequently died from recurrent lung metastases. No
patient had relapse in the para-aortic area. The
results are summarised in Table IV.
Table III Pathological classification of
patients having complete response (CR)
of para-aortic disease and those leaving a
residual mass (RM)
CR RM
TD 0 2
MTI 11 6
MTU 20 12
MTT 1 4
YS 1 1
Unclass 1 1
Total 34 26
TD=teratoma differentiated.
MTI=malignant teratoma intermediate.
MTU=malignant teratoma
undifferentiated.
MTT=malignant teratoma
trophoblastic.
YS =yolk sac tumour.
Residual mass patients
The stages of the patients at treatment were IIA6,
IIB 5, III3, IVA3, IVB6, IVC3. The size of the
initial para-aortic masses are shown in Table II.
The pathological classifications of the patients are
shown in Table III. The chemotherapy received by
the RM patients was PVB7, BEVIP 11, PEV 5 day
Table IV Outcome in relation to residual mass
CR RM
Total 34 26
Radiotherapy yes no yes no
27 (4b) 7 20 (2k) 6 (2k)
Alive no recurrence 21 (1b) 7 16 4
Relapsed (alive)
lung 2b
Relapsed (dead)
para-aortic 2c
stomach 1
lung lb
liver 1 1
brain 1 1
contralateral
testis 1
Dead (indeterminate) 1
aLaparotomy.
bXRT given as primary treatment.
cNo XRT after chemotherapy.626 G. READ et al.
4 and PEV24 hour 4. Six patients did not receive
radiotherapy following chemotherapy. One of these
patients had signs of inferior vena caval obstruction
and had a laparotomy immediately following
chemotherapy but only fibrosis was found. The
other five patients all had residual masses at other
sites.
Of the twenty patients who had radiotherapy 16
are alive with no evidence of further recurrence,
two of whom had a RPND with complete excision
of the residual mass 6 and 9 months after
completing radiotherapy because there was
suspicion of enlargement of the persisting mass.
Histology showed differentiated teratoma in one
and necrotic material in the other. Three patients
had relapsed, one in the stomach 34 months after
completing treatment, the para-aortic area being
negative at laparotomy, one in the liver with the
residual mass unchanged after six months and one
in the brain after 18 months. One patient died at
home of a presumed myocardial infarction.
Of the six patients who did not have
radiotherapy four are alive and well including one
who had enlargement of the retroperitoneal mass
and a supraclavicular node one year after
completing chemotherapy. Biopsy of the node and
the para-aortic mass showed differentiated
teratoma but complete resection was not possible.
Two patients had relapse in the para-aortic area
judged by radiological evidence of relapse
associated with rising tumour marker level 27 and
47 months after treatment. The cross-sectional areas
of the para-aortic masses of those patients with a
residual mass are shown in Table V before and
after chemotherapy and at a recent assessment.
Follow up scans were not available in 10 patients
for the following reasons: RPND3, died before
assessment 2, too heavy for scanner 1, patient
refused 2, relapsed in para-aortic area 2. Thus the
fate of the para-aortic mass was followed in the
remaining 16 patients. Seven had more than 75%
reduction in the size of the mass during the period
of observation and no change had taken place in 4
(Table VI).
Table V Cross-sectional areas ofpatients with residual masses
Cross-sectional areas ofpara-aortic masses (cm2)
% Reduction
Initial p/CT Recent p/CT Recent
314.2 141.1 102.1 55.0 27.8
181.4 44.2 no scan 75.6 no scan
Palpable 27.5 19.6 (28.6)a
62.8 19.6 RPND RPND
37.7 15.9 1.8 57.8 88.9
55.0 15.7 RPND 71.4 RPND
70.7 14.1 6.9 80.0 51.4
11.0 11.0 11.0 0 0(biopsy)
8.2 8.2 8.2 0 0
Palpable 8.2 0.8 90.5
Palpable 7.1 3.1 55.6
47.1 7.1 3.1 85.0 55.6
75.4 4.9 0.0 93.5 99.4
No scan 4.9 33.0 -572.Oa
15.7 4.9 1.6 68.7 68.0
19.6 3.1 no scan 84.0 No scan
19.6 3.1 3.1 84.0 0
Palpable 2.9 0.2 - 93.3
27.5 2.4 0.2 91.4 91.7
4.9 1.8 0.1 64.0 92.9
Palpable 1.8 Died Died
12.6 1.8 No scan 85.9 No scan
7.1 1.8 Died 75.0 Died
4.7 1.6 0.2 66.7 87.5
1.6 1.6 1.6 0.0 0.0
Palpable RPND RPND
p/CT post-chemotherapy. RPND retroperitoneal node dissection.
aRelapsed.RADIOTHERAPY AFTER CT IN NSGCT 627
Table VI % Reduction in cross-
sectional areas of residual para-
aortic masses from completion of
chemotherapy to recent scan
% Reductions in residual masses
>75% 7
5075% 4
26-50% 1
No change 4
Relapsed 2
Radiotherapy morbidity
The morbidity of radiotherapy given as a primary
treatment is well documented (Peckham et al.,
1981b). Only the 43 CR and RM patients receiving
radiotherapy post-chemotherapy are considered
here. The doses received are shown in Table VII.
No patient failed to complete the planned
radiotherapy treatment. During radiotherapy mild
nausea, abdominal colic and diarrhoea were
common but no patient developed symptoms severe
enough to warrant interruption of treatment. Some
myelosuppression during radiotherapy occurred in
all patients. Four patients had grade 1 leuocopenia
(>2.0 and <3.0x 1091-) and seven patients had
grade 2 leucopenia (> 1.0 and <2.0 x 1091-1). Two
patients had brief interruption of treatments but
there were no infective episodes. Five patients had
thrombocytopenia between 50 and 100 x 1091-1.
Subcutaneous fibrosis in the irradiated area
developing within six months of the conclusion of
radiotherapy was observed in 6 patients, in 3 of
whom it was sufficiently severe to produce some
restriction of movement. Fibrosis occurred in 4/8
patients in whom the subcutaneous dose exceeded
4,290cGy in 20 fractions in 28 days and 2/5
patients with a subcutaneous dose greater than
3,750cGy in 16 fractions over 21 days. In six patients
treated in the latter part of the present series and in
Table VII Radiotherapy doses given
post-chemotherapy
No. offractions
Midplane dose
(cGy) 16 20
4,000 - 33a
3,750 2 -
3,500 3 4
3,000 - 1
Total 5 38
15Q% of tumour dose given by rotation
in 6 patients.
patients treated subsequently 50% of the dose to
the para-aortic area has been delivered using a
rotation technique and no further cases of
subcutaneous fibrosis have been observed following
this modification which has also significantly
reduced myelosuppression.
Discussion
The aim of this study was to assess the results of
radiotherapy to the retroperitoneum following
chemotherapy in metastatic teratoma of the testis.
The relapse rate in the 'retroperitoneum was very
low - only 2/60 attaining CR or leaving a residual
mass - neither of whom had received radiotherapy
to the retroperitoneum. Although this was not a
randomised study there was no retroperitoneal
relapse in the 47 patients receiving radiotherapy
post-chemotherapy whereas 2/11 not receiving
radiotherapy or an immediate laparotomy relapsed.
One further patient with a palpable para-aortic
mass at presentation who did not have
reassassment or radiotherapy of the para-aortic
after chemotherapy subsequently relapsed in that
area.
Many centres advocate a retroperitoneal node
dissection (RPND) for residual masses following
chemotherapy. These operations are tedious and
may involve resection and or repair of the aorta,
inferior vena cava, bowel or ureter (Blandy, 1985)
since the object of surgery is complete removal of
the residual mass, not merely a biopsy (Rowland &
Donohoe, 1984). There may be considerable
morbidity in the form of post-operative back pain
and ejaculatory impotence. A complication rate of
25% and a mortality of 2-4% has been reported
(Donohoe & Rowland, 1981; Skinner et al., 1982).
In patients receiving RPND following chemo-
therapy the incidence of active tumour his high.
Rowland and Donohoe (1984) found tumour in
35% of patients following chemotherapy and Oliver
et al. (1983) found that one third of cases had
tumour. In a recent study (Vulgrin et al., 1985) of
patients treated by chemotherapy and RPND
malignant elements were found in 10/25 patients
achieving complete remission. In a review of the
experience of several centres Brenner et al. (1982)
found residual malignant elements in 32% of
patients. Only 7% of patients with necrosis, fibrosis
or benign teratoma relapsed compared with 61%
having residual malignancy. Although Tait et al.
(1984) suggest that the ultimate prognosis may
relate to the completeness or otherwise of the
resection, patients with active tumour still require
further chemotherapy as surgery is not curative in
its own right.628 G. READ et al.
In the present study 50/60 patients survived more
than two years with only two para-aortic
recurrences in patients not receiving radiotherapy.
This suggests that radiotherapy is effective in
sterilising minimal residual active tumour following
chemotherapy. Previous experience of treating stage
II patients by radiotherapy supports this since
relapse within the irradiated area of the -abdomen
was rare (Peckham et al., 1977). The morbidity of a
four week radical course of ratiotherapy is
negligible in comparison with RPND (Peckham &
Barrett, 1981b) and patients are spared further
salvage chemotherapy. Although it may be argued
that radiotherapy may compromise further
chemotherapy the fields used in this study
encompassed only the para-aortic area thereby
keeping the volume of marrow irradiated to a
minimum. This has been reduced further by
delivering 50% of the tumour dose by a rotation
technique rather than parallel opposed fields. This
study also suggests that following radiotherapy
residual masses may be safely observed since the
majority will show a substantial reduction in size
with the passage of time.
In conclusion this study suggests that the use of
radiotherapy provides an alternative approach to
the use of surgery post-chemotherapy in patients
with para-aortic nodal disease. This approach
spares patients the inconvenience and morbidity of
a prolonged surgical procedure and the need for
further chemotherapy should active tumour be
found. Further studies are required to determine
whether radiotherapy, is required in all patients or
only those in whom there is a residual mass.
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